SecBot SecBot
144 ·Filed Aug 12, 2026

RPRX

Royalty Pharma plc
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001968582-26-000828
Actionable Insight • Neutral

Monitor for actual Form 4 filings to confirm execution of these sales. The trust restructuring and conversion of LP interests suggest a planned liquidity event rather than opportunistic selling. Given the former-affiliate status and the shares' origin from legacy LP interests, this is not a red flag for current management's confidence. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$58.56
T+0 close · Aug 12, 2026 · via day close
Latest settled
+15.10%
T+60 · $67.40
Vs SPY
+20.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $58.56entry
  2. T+1 · 3mo ago +0.07%α +0.27% · $58.60
  3. T+5 · 3mo ago +3.45%α +5.41% · $60.58
  4. T+20 · 2mo ago +0.09%α +1.83% · $58.61
  5. T+60 · 11d ago +15.10%α +20.34% · $67.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Errol B. De Souza, a former affiliate of Royalty Pharma, filed two Form 144 notices on August 12, 2026, signaling intent to sell a combined 331,352 Class A ordinary shares. The first filing covers 206,352 shares (approx. $11.9M at the filing date) from the Errol Bento De Souza Revocable Trust, and the second covers 125,000 shares (approx. $7.2M) from the De Souza 2021 Irrevocable Trust. Both blocks were acquired via conversion of LP interests on August 7, 2026, and are being sold through J.P. Morgan. While the total ~$19.1M sale is notable, De Souza is a former affiliate (not current management), and the shares originate from a trust restructuring, not an open-market accumulation, reducing the signal of negative insider sentiment. Impact is neutral-to-low, this is a planned liquidity event, not a distress signal.

Key Facts

  • Errol B. De Souza, a former affiliate, filed two Form 144 notices to sell a total of 331,352 Class A ordinary shares of Royalty Pharma.
  • First filing: 206,352 shares (~$11.9M) from the Errol Bento De Souza Revocable Trust.
  • Second filing: 125,000 shares (~$7.2M) from the De Souza 2021 Irrevocable Trust.
  • Both share blocks were acquired on August 7, 2026, via conversion of LP interests originally received from the issuer on June 16, 2020.
  • Sales are to be executed through J.P. Morgan Securities LLC as agent.
  • De Souza is a former affiliate, not current management, reducing the insider-signal weight.

Financial Impact

Combined proposed sale of 331,352 shares valued at approximately $19.1 million based on filing-date prices ($11.9M + $7.2M).

dilution

Risk Factors

  • If additional former affiliates or current management file similar large 144s in the coming weeks, it could signal broader insider distribution.
  • Execution of the full 331,352 shares over a short period could create modest selling pressure, though the $19.1M total is small relative to RPRX's $33.2B market cap (0.06%).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (RPRX), Batch item 10001968582-26-000828
Document: 0001968582-26-000828-index.html0001968582-26-000827
Document: 0001968582-26-000828.txt0001968582-26-000828
144 Filing (RPRX), Batch item 40001968582-26-000827
Document: 0001968582-26-000827-index.html0001968582-26-000828
Document: 0001968582-26-000827.txt0001968582-26-000828

Track record

23 reports on RPRX

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $69.31 +2.58% ▲ +2.07% −1.22% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  4. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $69.31 +2.59% ▲ +3.63% +4.54% vs SPY
  5. Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $69.31 −20.27% ▲ +2.46% +3.77% vs SPY
  6. Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $69.31 −14.39% ▲ +3.50% +2.38% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $69.31 +14.44% ▲ +2.24% +1.12% vs SPY
  8. Aug 12, 202613w ago 144 Neutral 3/10 Viewing Entry $58.56 to $60.58 Now $69.31 +18.36% ▲ +3.45% +5.41% vs SPY
  9. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $69.31 +20.02% ▲ +2.55% +2.19% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $69.31 +19.98% ▲ +0.33% −0.60% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026